J & J to buy rights for experimental skin disorder drug for $1.25 billion
Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.
Drugs
Health
Pharma
Drugs
Health
Pharma
J&J’s metastatic bladder cancer drug gets full FDA approval
HQ Team January 21, 2024: The FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical.
Drugs
Health
Pharma
J&J to purchase Ambrx Biopharma for $2 billion in all-cash deal
HQ Team January 8, 2023: Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash..
Drugs
Health
Pharma
J&J’s consumer division Kenvue floats $41bn IPO
Johnson & Johnson consumer arm Kenvue floats biggest US IPO since 2021. Kenvue is valued at $41bn after being divisioned off from US.
Pharma
Uncategorized
J&J acquires cardio tech maker Abiomed for $16.6bn
J&J acquires cardiovascular medtech developer Abiomed for $16.6 billion